Laurent Pharmaceuticals Inc.

13 articles with Laurent Pharmaceuticals Inc.

• Laurent Pharmaceuticals Completes Patients Enrollment in Phase 2 Study of LAU-7b for the Treatment of COVID-19

  5/20/2021

  Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing the first-in-class pro-resolving drug LAU-7b, today announces that it has completed the enrollment for its placebo-controlled Phase 2 RESOLUTION clinical study of hospitalized patients with COVID-19. The study, which enrolled 240 patients across Canada and United States, is expected to report top-line results in Q3 2021.

• Laurent Pharmaceuticals Provides Clinical Development Update

  4/8/2021

  Laurent Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing first-in-class pro-resolving drug LAU-7b, today announces that the independent Data Safety Monitoring Board (DSMB) for the Phase 2 RESOLUTION study in hospitalized patients with COVID-19

• Laurent Pharmaceuticals Receives Approval from FDA to Initiate its COVID-19 Phase 2 Clinical Trial in the United States

  8/27/2020

  The Phase 2 study aims to evaluate the dual antiviral and inflammation-controlling effects of the company's LAU-7b oral drug candidate against COVID-19 infection

• Laurent Pharmaceuticals Receives Health Canada’s Approval to Initiate COVID-19 Clinical Trial

  5/6/2020

  Company to test LAU-7b’s dual pro-resolving inflammation and antiviral properties against COVID-19

• 

  Biopharma Update on the Novel Coronavirus: May 6

  5/6/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 6, 2020.
• 

  Clinical Catch-Up: April 6-10

  4/13/2020

  It was a very busy week for clinical trial news. Here’s a look.

• Laurent Pharmaceuticals Joins Battle Against COVID-19

  4/9/2020

  Laurent Pharmaceuticals to initiate world-first testing of LAU-7b in COVID-19 patients

• Laurent Pharmaceuticals Receives a CAD 2.7M Financing from BioMed Propulsion Fund

  12/4/2019

  LAU-7b is an oral drug acting on the resolution phase of the inflammation, with the potential to treat chronic pulmonary inflammation that leads to irreversible lung damage in patients with CF.

• Laurent Pharmaceuticals Receives an Additional up to $3M Award from Cystic Fibrosis Foundation

  10/31/2019

  This adds to the US$ 5 million development award already made available by the Foundation.

• Laurent Pharmaceuticals Welcomes New Investors and Announces Scientific Breakthrough with LAU-7b in Cystic Fibrosis

  10/25/2018

  Laurent Pharmaceuticals Inc. today announced new financing led by Keiretsu Forum Mid-Atlantic, Anges Quebec and Anges Quebec Capital, with participation from existing investors RSJ Gradus, Aligo Innovation, and Cystic Fibrosis Canada. Members from other Keiretsu Forum chapters also invested, as well as a select group of new and existing private individuals.

• Laurent Receives FDA And Health Canada Clearance To Initiate APPLAUD Phase II Clinical Study Of LAU-7b For The Treatment Of Cystic Fibrosis

  4/19/2017

• Laurent Receives $3 Million Development Award From Cystic Fibrosis Foundation Therapeutics, Inc.

  7/26/2016

• Laurent To Receive Investment From Cystic Fibrosis Canada

  3/17/2016